SCK CEN And IBA Cooperate To Enable The Production Of Actinium-225
SCK CEN – Belgian Nuclear Research Center (ENS Corporate Member) and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announced a strategic R&D partnership to enable the production of Actinium-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
Alpha-emitting Actinium-225 is one of the most promising radioisotopes for the development of nuclear medicine.
This is due to its useful characteristics: in its decay, it kills cancer cells, having high cytotoxic potency within a very short range (limited to few cancerous cells while sparing surrounding healthy tissues).
Moreover, its half-life (10 days) enables a smooth process for logistics and centralized distribution.
One of the main challenges to making this therapeutic solution accessible for the greatest number of patients is ensuring the availability of high-quality Actinium-225 in large quantities.
Read the full SCK CEN Press Release.